Transthyretin amyloidosis (ATTR): cross-border specialty drug access for international patients

Quick orientation

Hereditary ATTR amyloidosis is estimated to affect 50,000 to 110,000 people worldwide. Wild-type ATTR cardiomyopathy is increasingly recognized in older adults; autopsy series suggest up to 25 percent of people over 80 have some degree of cardiac TTR deposition, though clinically apparent disease is far less common.

Typical age of onset. Hereditary forms typically present between ages 30 and 70 depending on variant; wild-type ATTR is generally diagnosed after age 65.

Severity tiers. Untreated, ATTR is progressive and life-limiting. Polyneuropathy-predominant and cardiomyopathy-predominant presentations differ in dominant symptoms, prognosis, and trial-evidence base.

Why specialty drugs for Transthyretin amyloidosis (ATTR) are hard to access internationally

Multiple TTR stabilizers and TTR silencers have been approved by the FDA in the last several years, with new approvals as recent as 2024 and 2025. Most are not yet registered in MENA or South Asia, and where they are, payer access is restricted to narrow patient profiles. The drugs are also priced at levels that make local out-of-pocket purchase impractical even when commercially available, and most require continuous lifelong administration.

Treatments approved by the FDA

• Amvuttra (vutrisiran) — FDA approval: 2022 (cardiomyopathy 2025). Mechanism: RNA interference therapeutic that silences hepatic TTR production. Route: Subcutaneous injection every 3 months. US WAC ballpark: Approximately USD 475,000 per year. Country pricing: Saudi Arabia · Bahrain · Oman.
• Attruby (acoramidis) — FDA approval: 2024. Mechanism: Selective TTR stabilizer. Route: Oral twice daily. US WAC ballpark: Approximately USD 240,000 per year. Country pricing: UAE · Saudi Arabia · Qatar · Kuwait.
• Wainua (eplontersen) — FDA approval: 2023. Mechanism: Antisense oligonucleotide that reduces TTR production. Route: Subcutaneous injection monthly. US WAC ballpark: Approximately USD 400,000 per year. Country pricing: UAE · Egypt · Bahrain · Lebanon.
• Vyndamax (tafamidis) — FDA approval: 2019. Mechanism: TTR stabilizer. Route: Oral once daily. US WAC ballpark: Approximately USD 225,000 per year.

Cross-border pathways used for Transthyretin amyloidosis (ATTR)

Most patients use one or more of the following regulatory pathways, depending on the destination country and the specific drug:

• Named Patient Program (NPP)
• Expanded Access Program (EAP)
• Compassionate Use
• Personal Import Scheme

What your physician needs to know

• Confirm TTR genotype, predominant phenotype (polyneuropathy versus cardiomyopathy), and NYHA class before drug selection.
• Cardiac MRI, technetium pyrophosphate scintigraphy, and NT-proBNP inform staging.
• Silencer and stabilizer therapies are not directly comparable; treatment choice depends on stage, organ involvement, and patient preference.
• Some destination countries require a treating cardiologist or neurologist with documented amyloidosis experience.
• Anti-TTR therapies are intended for indefinite duration; international supply continuity matters more than for short courses.

Common questions

Which ATTR drug is right for my case?

That depends on phenotype, stage, and tolerability. Your treating cardiologist or neurologist will recommend a regimen; Reserve Meds supports access to whichever specific drug is prescribed.

Can I switch between drugs over time?

Switching is clinically feasible and sometimes indicated. We can support sequential international supply when the regimen changes.

Does Reserve Meds dispense these drugs?

We coordinate cross-border access. The drug is dispensed by a US-licensed pharmacy after appropriate clinical and regulatory review.

How long does a typical shipment take?

Five to fifteen business days from prescription receipt, depending on destination import requirements and product type.

Are these drugs registered in my country?

Registration varies. Vyndamax is the most widely registered globally; the newer drugs are still rolling out. We confirm current status by destination.

What documents are required?

Treating physician's prescription, clinical summary including TTR genotype if known, and any country-specific import documentation.

Where Reserve Meds fits in

Reserve Meds is a cross-border specialty drug access platform. We support international patients whose prescribed FDA-approved medicine is not registered locally, is not reimbursed by their payer, or is otherwise unavailable through standard channels. For Transthyretin amyloidosis (ATTR), our role is to coordinate the regulatory pathway, source the medicine from a DSCSA-compliant US wholesaler, and arrange validated cold-chain or controlled-temperature shipment to the destination country.

We do not replace your treating physician. We do not bill insurance. We operate a cash-pay model, and we work alongside the clinical team that knows your case. Every prescription is reviewed by a US-licensed pharmacist before dispense, and a US-licensed physician reviews the supply request before shipment.

Start a request

Request a drug for Transthyretin amyloidosis (ATTR)

Reserved for you.